Literature DB >> 27042875

Cigarette Smoking, BPDE-DNA Adducts, and Aberrant Promoter Methylations of Tumor Suppressor Genes (TSGs) in NSCLC from Chinese Population.

Yongtang Jin1, Peiwei Xu1, Xinneng Liu1, Chunye Zhang1, Cong Tan1, Chunmei Chen1, Xiaoyu Sun1, Yingchun Xu2.   

Abstract

Non-small cell lung cancer (NSCLC) is related to the genetic and epigenetic factors. The goal of this study was to determine association of cigarette smoking and BPDE-DNA adducts with promoter methylations of several genes in NSCLC. Methylation of the promoters of p16, RARβ, DAPK, MGMT, and TIMP-3 genes of tumor tissues from 199 lung cancer patients was analyzed with methylation-specific PCR (MSP), and BPDE-DNA adduct level in lung cancer tissue was obtained by ELISA. Level of BPDE-DNA adduct increased significantly in males, aged people (over 60 years), and smokers; however, no significant difference was found while comparing the BPDE-DNA adduct levels among different tumor types, locations, and stages. Cigarette smoking was also associated with increased BPDE-DNA adducts level (OR = 2.43, p > .05) and increased methylation level in at least 1 gene (OR = 5.22, p < .01), both in dose-response manner. Similarly, cigarette smoking also significantly increase the risk of p16 or DAPK methylation (OR = 3.02, p < .05 for p16, and 3.66, p < .05 for DAPK). The highest risk of BPDE-DNA adducts was detected among individuals with cigarette smoking for more than 40 pack-years (OR = 4.21, p < .01). Furthermore, the present study did not show that BPDE-DNA adducts are significantly associated with abnormal TSGs methylations in NSCLC, including SCC and AdO, respectively. Conclusively, cigarette smoking is significantly associated with the increase of BPDE-DNA adduct level, promoter hypermethylation of p16 and DAPK genes, while BPDE-DNA adduct was not significantly related to abnormal promoter hypermethylation in TSGs, suggesting that BPDE-DNA adducts and TSGs methylations play independent roles in NSCLC.

Entities:  

Keywords:  Cigarette smoking; DNA adduct; Gene methylation; Lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27042875     DOI: 10.3109/07357907.2016.1156689

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

Review 1.  Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: An update of a systematic literature review.

Authors:  Samantha Goodman; Grace Chappell; Kathryn Z Guyton; Igor P Pogribny; Ivan Rusyn
Journal:  Mutat Res Rev Mutat Res       Date:  2021-12-09       Impact factor: 7.015

Review 2.  [Progress of Epigenetic Methylation in Lung Cancer Research].

Authors:  Shaowei Zhang; Zhiqiang Xue
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-09-20

3.  Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Yan Zhang; Jiang Wu; Gui Huang; Shouming Xu
Journal:  Cancer Manag Res       Date:  2018-12-12       Impact factor: 3.989

4.  Epigenome-wide association study of smoking and DNA methylation in non-small cell lung neoplasms.

Authors:  Joshua R Freeman; Su Chu; Thomas Hsu; Yen-Tsung Huang
Journal:  Oncotarget       Date:  2016-10-25

5.  Analysis of H3K27me3 expression and DNA methylation at CCGG sites in smoking and non-smoking patients with non-small cell lung cancer and their clinical significance.

Authors:  Kunshou Zhu; Yujie Deng; Guoxing Weng; Dan Hu; Cheng Huang; Keitaro Matsumoto; Takeshi Nagayasu; Takehiko Koji; Xiongwei Zheng; Wenhui Jiang; Gen Lin; Yibin Cai; Guibin Weng; Xiaohui Chen
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

6.  Systems biology analysis of publicly available transcriptomic data reveals a critical link between AKR1B10 gene expression, smoking and occurrence of lung cancer.

Authors:  Juan M Cubillos-Angulo; Eduardo R Fukutani; Luís A B Cruz; María B Arriaga; João Victor Lima; Bruno B Andrade; Artur T L Queiroz; Kiyoshi F Fukutani
Journal:  PLoS One       Date:  2020-02-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.